Analysis of Severe Adverse Events Reported Among Patients Receiving Isoniazid-Rifapentine Treatment for Latent Mycobacterium tuberculosis Infection—United States, 2012–2016
Open Access
- 18 March 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 71 (9), 2502-2505
- https://doi.org/10.1093/cid/ciaa286
Abstract
We analyzed data from 2012 to 2016 for patients who were hospitalized or who died after ≥1 dose of isoniazid-rifapentine for treatment of latent Mycobacterium tuberculosis infection. No patients died; 15 were hospitalized. Nine patients experienced hypotension, and 5 had elevated serum aminotransferases, reinforcing the need for vigilant monitoring during treatment.This publication has 14 references indexed in Scilit:
- Recent Transmission of Tuberculosis — United States, 2011–2014PLOS ONE, 2016
- Tuberculosis Infection in the United States: Prevalence Estimates from the National Health and Nutrition Examination Survey, 2011-2012PLOS ONE, 2015
- Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.The International Journal of Tuberculosis and Lung Disease, 2015
- Faculty Opinions recommendation of Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection.Published by H1 Connect ,2012
- Three Months of Rifapentine and Isoniazid for Latent Tuberculosis InfectionThe New England Journal of Medicine, 2011
- Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection - United States, 2004-2008.2010
- Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America.2005
- Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003.2003
- Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.2001
- Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society.2000